RAPP

ANALYST NOTE: RAPP (Rapport Therapeutics, Inc.) Date: 2026-06-13 Analyst: StoryStocks-Native Equity Research

1. Structural Readiness

As of the close on 2026-06-13, RAPP is trading at $42.56. The setup is classified as a confirmed coil breakout with a Conservative Entry level of $42.62. The current price sits at an extension of -0.1% relative to this entry, indicating the stock is testing the breakout threshold with minimal deviation.

The setup exhibits very high structural quality, evidenced by an ATR at breakout of 6.2% and a current ATR of 6.5%. This volatility profile places the stock in the "very high" bucket (6–8%), suggesting significant institutional interest and liquidity depth at the time of the setup formation. The presence of a confirmed coil indicates that the base has formed and the breakout signal has fired, providing a positive readiness signal. There is no evidence of a setup violation or invalidation; the structure remains intact as the price hovers immediately adjacent to the entry trigger.

2. The Thesis Layer

The primary secular thesis driving this setup is Biotech & GLP-1 → Neuro / CNS, with a high confidence rating on direct exposure. RAPP operates as a direct beneficiary within this theme, focusing on precision medicines for neurological and psychiatric disorders.

While the company is not a direct GLP-1 developer, its pipeline targets the broader CNS market, which is increasingly intersecting with metabolic and neurodegenerative pathways. The company's role is that of a clinical-stage innovator developing small molecules to inhibit TARPy8-containing AMPARs. This positions RAPP as a high-conviction play on the "Neuro" tier of the Biotech & GLP-1 theme, leveraging the secular tailwinds of unmet needs in epilepsy and bipolar disorder. The directness of the exposure is high, as the company's core asset, RAP-219, is specifically designed for these indications.

3. The Business

Rapport Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The company's business model relies on the development and potential commercialization of proprietary assets, supplemented by strategic licensing and partnership agreements.

Key Business Developments (as of 2026-06-13):

• Capitalization: The company recently secured significant liquidity. As reported in filings dated 2026-05-07, the company completed an underwritten follow-on public offering in September 2025, generating $269.4 million in net proceeds.
• Strategic Partnership: On March 6, 2026, the company entered into a License Agreement with Tenacia. Under this agreement, Tenacia received exclusive rights to develop and commercialize RAP-219 in mainland China, Hong Kong, Macau, and Taiwan. In exchange, Rapport received a $20.0 million non-refundable upfront payment.
• Clinical Progress: The company announced positive topline results from its Phase 2a proof-of-concept trial of RAP-219 in adult patients with drug-resistant FOS (Focal Onset Seizures) in September 2025. Furthermore, FDA feedback received in December 2025 supported the advancement into two Phase 3 trials for FOS, with management expecting to initiate this program in the second quarter of 2026.
• Pipeline Expansion: Management has indicated plans to initiate a Phase 3 trial in PGTCS (Post-Traumatic Global Cognitive Syndrome) in the first half of 2027. Additionally, a Phase 2 trial in bipolar mania is currently enrolling, with topline results expected in the first half of 2027.
• Market Context: The company notes that an estimated 1.8 million people in the United States suffer from FOS, representing approximately 60% of patients with epilepsy. The total branded market for epilepsy was approximately $2.8 billion in 2022, with management expectations of growth to $3.6 billion by 2028.

4. Archetype and Conviction

RAPP fits the Deep Value Recovery archetype. This classification is driven by the convergence of a strong balance sheet (post-offering and licensing revenue), positive clinical data (Phase 2a success), and a clear path to Phase 3 initiation, all occurring while the stock trades at a level that reflects a recovery from earlier valuation compression.

Valuation and Financial Context:

• Financial Spine: The financial spine coverage is complete, with forward consensus EPS for FY1 at -3.36 and FY2 at -4.33. While the company remains unprofitable, the negative EPS is consistent with a clinical-stage biotech in the investment phase, and the recent capital raises ($269.4M + $20M) provide a runway to fund operations through at least 12 months from the May 2026 filing date.
• ATR Analysis: The current ATR of 6.5% (very high) suggests elevated volatility, which is typical for biotech names approaching pivotal data or breakout points. This volatility is a structural feature of the setup, indicating active trading and potential for significant price movement, rather than a sign of weakness.
• Conviction Stack: The conviction is supported by the strength of the secular thesis (Neuro/CNS), the quality of the evidence (positive Phase 2a, FDA support, strategic licensing), and the structural readiness (confirmed coil). The rerating potential is tied to the successful initiation of Phase 3 trials and the commercialization of the Tenacia territory.

5. Invalidations, Strengtheners, and Gaps

What Would Strengthen the Case:

• Successful initiation of the Phase 3 FOS program as planned in Q2 2026.
• Positive interim data or enrollment milestones from the bipolar mania trial.
• Additional strategic partnerships or licensing deals outside the Tenacia territory.
• Continued strong institutional accumulation following the breakout.

What Would Invalidate the Case:

• A significant delay in the Phase 3 initiation beyond the Q2 2026 window without a clear, communicated reason.
• Negative feedback from the FDA regarding the Phase 3 trial design.
• A breach of the cash runway (e.g., inability to fund operations through the 12-month horizon stated in the May 2026 filing).
• A sustained breakdown below the structural base with volume confirmation, indicating a failure of the breakout.

Gaps in the Evidence Base:

• Commercialization Timeline: While the Tenacia deal provides upfront cash, the specific timeline for revenue recognition from the Tenacia territory and the potential for milestone payments is not detailed in the provided evidence.
• Competitive Landscape: The evidence does not explicitly detail the competitive set for RAP-219 in the FOS market, which is a critical factor for long-term valuation.
• Dilution Risk: While the recent offering was successful, the evidence does not quantify the potential for future dilution if additional capital is required before Phase 3 data readouts.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: high Key evidence: Confirmed coil breakout with very high ATR; $269.4M follow-on offering and $20M upfront licensing payment securing runway; Positive Phase 2a topline results and FDA support for Phase 3 initiation. Key risks: Clinical trial delays or negative Phase 3 data; potential future dilution if capital needs exceed current runway; high volatility (6.5% ATR) leading to sharp drawdowns. Rating boundary: This is a Buy rather than a Strong Buy because the company is still pre-revenue and reliant on the successful execution of upcoming Phase 3 trials, which introduces binary clinical risk that prevents a top-tier conviction. It would drop to a Speculative rating if the Phase 3 initiation is delayed beyond Q2 2026 or if the cash runway is threatened. Sizing hint: Position size should reflect the high ATR and binary clinical nature; standard biotech sizing with a focus on the confirmed setup structure. Expected path: Management expects to initiate Phase 3 in FOS in Q2 2026, followed by a multi-year development timeline for PGTCS and bipolar mania, with the Tenacia deal providing near-term cash flow. Expected horizon: 12 to 24 months for the Phase 3 initiation and early data readouts to drive the next valuation inflection. Failure mode to watch: A failure to initiate the Phase 3 FOS program in Q2 2026 as stated by management, which would signal execution risk and potentially erode the structural setup.